The use of biologic therapies for the management of pediatric asthma

被引：21

作者：

Lovinsky-Desir, Stephanie ^{[1
]}

机构：

[1] Columbia Univ, Dept Phys, Coll Phys & Surg, Div Pediat Pulmonol, 538 W 120th St, New York, NY 10027 USA

来源：

PEDIATRIC PULMONOLOGY | 2020年 / 55卷 / 03期

关键词：

anti-eosinophil therapy; anti-IgE therapy; childhood asthma; monoclonal antibodies; T-helper; 2; asthma; COST-EFFECTIVENESS; ALLERGIC-ASTHMA; AIR-POLLUTANTS; OMALIZUMAB; CHILDREN;

D O I：

10.1002/ppul.24613

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

With better understanding of the role of type 2 inflammation in allergic asthma, there has been progress made in the development of new biologic therapies targeting these specific pathways. This review will consider diagnostic criteria for using biologic therapies for pediatric asthma with special emphasis on populations that are likely to benefit the most from particular therapies. With the exception of the anti-immunoglobulin E, omalizumab, very few studies have been published on the efficacy and safety of biologic therapies in children, particularly anti-interleukin-5 (IL5) and anti-IL4/IL13 therapies. The review will highlight the scarcity of published data in pediatric-specific populations. In addition, we will consider the cost-effectiveness as well as potential long-term consequences of biologic therapies in pediatric asthma.

引用

页码：803 / 808

页数：6

共 38 条

[1] Adrenergic Signaling at the Interface of Allergic Asthma and Viral Infections
Agac, Didem
Gill, Michelle A.
Farrar, J. David
[J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
[2] Cost-effectiveness and comparative effectiveness of biologic therapy for asthma To biologic or not to biologic?
Anderson, William C., III
Szefler, Stanley J.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 122 (04) : 367 - 372
[3] AstraZeneca Pharmaceuticals LP, BENRALIZUMAB FASENRA
[4] Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, Elisabeth H.
Wenzel, Sally E.
Thompson, Philip J.
Prazma, Charlene M.
Keene, Oliver N.
Yancey, Steven W.
Ortega, Hector G.
Pavord, Ian D.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) : 1189 - 1197
[5] Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma
Berger, W
Gupta, N
McAlary, M
Fowler-Taylor, A
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2003, 91 (02) : 182 - 188
[6] Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
Bleecker, Eugene R.
Wechsler, Michael E.
FitzGerald, J. Mark
Menzies-Gow, Andrew
Wu, Yanping
Hirsch, Ian
Goldman, Mitchell
Newbold, Paul
Zangrilli, James G.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (04)
[7] Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Bleecker, Eugene R.
FitzGerald, J. Mark
Chanez, Pascal
Papi, Alberto
Weinstein, Steven F.
Barker, Peter
Sproule, Stephanie
Gilmartin, Geoffrey
Aurivillius, Magnus
Werkstrom, Viktoria
Goldman, Mitchell
[J]. LANCET, 2016, 388 (10056) : 2115 - 2127
[8] The oral corticosteroid-sparing effect of omalizumab in children with severe asthma
Brodlie, Malcolm
McKean, Michael C.
Moss, Samantha
Spencer, David A.
[J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2012, 97 (07) : 604 - +
[9] Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma
Brown, R.
Turk, F.
Dale, P.
Bousquet, J.
[J]. ALLERGY, 2007, 62 (02) : 149 - 153
[10] Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, William W.
Morgan, Wayne J.
Gergen, Peter J.
Mitchell, Herman E.
Gern, James E.
Liu, Andrew H.
Gruchalla, Rebecca S.
Kattan, Meyer
Teach, Stephen J.
Pongracic, Jacqueline A.
Chmiel, James F.
Steinbach, Suzanne F.
Calatroni, Agustin
Togias, Alkis
Thompson, Katherine M.
Szefler, Stanley J.
Sorkness, Christine A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (11) : 1005 - 1015

← 1 2 3 4 →